Last updated: September 17, 2026
Ocrelizumab, marketed by Roche as Ocrevus, is the leading anti-CD20 therapy for multiple sclerosis. Roche reported approximately CHF 7.1 billion in Ocrevus sales in 2024, up from about CHF 6.4 billion in 2023. Growth is supported by switching from older disease-modifying therapies, continued uptake in primary progressive multiple sclerosis, six-month dosing, and the 2024 U.S. approval of a subcutaneous formulation.
The principal medium-term risks are increasing competition in relapsing multiple sclerosis, Medicare and payer pricing pressure, potential biosimilar development after U.S. reference-product exclusivity expires in 2029, and competition from high-efficacy oral and extended-duration therapies.
What is ocrelizumab and how does Ocrevus generate revenue?
Ocrelizumab is a humanized monoclonal antibody that binds CD20-positive B cells. B-cell depletion reduces inflammatory activity associated with multiple sclerosis. Roche sells Ocrevus in two principal formats:
| Product |
Route |
Primary use |
Dosing |
| Ocrevus IV |
Intravenous infusion |
Relapsing forms of multiple sclerosis and primary progressive multiple sclerosis |
Every six months after initial split dosing |
| Ocrevus Zunovo |
Subcutaneous injection |
Relapsing forms and primary progressive multiple sclerosis in the U.S. |
Every six months after an initial IV dose |
The FDA approved intravenous Ocrevus in March 2017 for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis. It was the first disease-modifying therapy approved in the United States for primary progressive multiple sclerosis (FDA, 2017).
In September 2024, the FDA approved Ocrevus Zunovo, a fixed-dose combination of ocrelizumab and recombinant human hyaluronidase. The product is administered subcutaneously over approximately 10 minutes, reducing infusion-center time compared with intravenous treatment (FDA, 2024).
How have Ocrevus sales and Roche revenue developed?
Ocrevus has become one of Roche’s largest products and a central contributor to the company’s pharmaceutical portfolio.
| Year |
Approximate Roche Ocrevus sales |
Commercial trend |
| 2022 |
CHF 5.7 billion |
Continued patient additions and switching |
| 2023 |
CHF 6.4 billion |
Strong demand across relapsing and progressive disease |
| 2024 |
CHF 7.1 billion |
Continued volume growth and subcutaneous launch preparation |
Sources: Roche annual reports and financial releases (Roche, 2023, 2024).
The trajectory reflects several factors:
- Ocrevus has broad labeling across relapsing multiple sclerosis and primary progressive multiple sclerosis.
- Six-month administration reduces dosing frequency relative to daily or weekly alternatives.
- Physicians have increasingly adopted high-efficacy treatment earlier in the multiple sclerosis treatment sequence.
- Patients have switched from older injectable therapies, including interferon and glatiramer acetate.
- The product has retained significant commercial value despite competition from oral drugs and other anti-CD20 therapies.
Revenue growth should moderate as the product reaches a larger treated base. The subcutaneous formulation can extend the franchise by improving convenience, preserving Roche’s relationship with existing patients, and reducing healthcare-provider administration burden.
When does ocrelizumab lose exclusivity?
U.S. biologic exclusivity for Ocrevus expires on March 28, 2029, based on the FDA’s 12-year reference-product exclusivity period beginning with the 2017 approval. A biosimilar sponsor could submit an application four years after the reference product’s approval, but the FDA cannot approve the biosimilar before the 12-year exclusivity period ends under the Biologics Price Competition and Innovation Act (FDA, 2020).
The practical loss-of-exclusivity date can differ from the nominal biologic exclusivity date because of patents, settlements, manufacturing complexity, and biosimilar litigation.
| Jurisdiction |
Key exclusivity framework |
Ocrelizumab timing |
| United States |
12 years of reference-product exclusivity |
March 2029 |
| European Union |
Eight years of data exclusivity plus two years of market protection, with a possible one-year extension |
Core protection generally reaches the late 2020s |
| Other markets |
Country-specific biologic and patent rules |
Varies by jurisdiction |
The European Union authorized Ocrevus in January 2018. The EU regulatory exclusivity framework is separate from U.S. exclusivity and does not create a single global biosimilar-entry date (European Medicines Agency, 2018).
What patents protect Ocrevus?
Ocrevus is protected by a portfolio rather than by a single patent. The relevant categories include:
- Anti-CD20 antibody composition claims.
- Antibody sequence and binding claims.
- Methods of treating relapsing multiple sclerosis.
- Methods of treating primary progressive multiple sclerosis.
- Dosing and administration regimens.
- Pharmaceutical formulations.
- Subcutaneous delivery using hyaluronidase.
- Manufacturing, cell-line, purification, and quality-control processes.
Biologic patent analysis is less transparent than small-molecule analysis because the FDA Orange Book does not provide the principal patent listing mechanism for biologics. Ocrevus is therefore not evaluated through a conventional Orange Book patent table in the same way as an oral chemical drug. Biosimilar sponsors must consider the reference-product patent portfolio through the BPCIA patent-exchange process, commonly called the patent dance.
The most commercially important patents are likely to be those covering the antibody, the subcutaneous presentation, dosing methods, and manufacturing processes. Method-of-use and formulation patents can delay or limit launch even after core composition protection becomes vulnerable.
Patent expiration dates must be assessed patent by patent and jurisdiction by jurisdiction. The 2029 U.S. biologic exclusivity date should not be treated as a complete statement of Ocrevus patent protection.
What is the Orange Book status of Ocrevus?
Ocrevus does not have the same Orange Book listing profile as a conventional small-molecule drug. It is regulated as a biologic, and biosimilar applicants use the Purple Book and BPCIA framework rather than an abbreviated new drug application under Section 505(j).
The regulatory implications are significant:
- A generic drug application is not the normal route for ocrelizumab.
- A competing product would generally require a biosimilar application under Section 351(k).
- The biosimilar must demonstrate high similarity and no clinically meaningful differences from Ocrevus.
- Interchangeability requires additional FDA requirements beyond biosimilarity.
- A biosimilar may initially launch with narrower labeling if method-of-use claims remain protected.
Which companies are challenging Ocrevus?
No FDA-approved ocrelizumab biosimilar was publicly established through 2024. No major publicly disclosed U.S. Paragraph IV litigation was associated with Ocrevus in the manner commonly seen for small-molecule products.
The absence of a public challenge does not eliminate future biosimilar risk. Ocrelizumab is an attractive target because:
- Annual sales exceed CHF 7 billion.
- The product has a large and growing patient base.
- The molecule has a validated mechanism and established clinical demand.
- Anti-CD20 manufacturing capabilities are already available through several large biologics manufacturers.
- The 2029 U.S. exclusivity date provides a clear development horizon.
The main barriers are clinical comparability, immunogenicity testing, manufacturing scale, analytical characterization, and access to reference-product material. Anti-CD20 competition also includes rituximab biosimilars, which provide manufacturing and regulatory experience relevant to future ocrelizumab programs.
How strong is the Ocrevus patent estate?
The Ocrevus estate is commercially strong but not immune to erosion.
Strengths
The product has multiple layers of protection across:
- Reference-product regulatory exclusivity.
- Antibody composition and sequence claims.
- Treatment methods.
- Dosing regimens.
- Intravenous and subcutaneous formulations.
- Manufacturing and process technology.
- Brand, physician familiarity, and market access.
The approval of Ocrevus Zunovo creates a differentiated delivery platform. Even if a biosimilar reaches the market, Roche may retain patients who value the subcutaneous formulation or whose physicians prefer the established product.
Weaknesses
The core mechanism is clinically validated and technically reproducible. Biosimilar developers do not need to reproduce Roche’s original discovery program. They need to establish analytical similarity, comparable clinical performance, and adequate immunogenicity data.
The product also faces a concentration risk: a substantial portion of Roche’s multiple sclerosis revenue is tied to one anti-CD20 franchise. As treatment guidelines evolve, physicians may move patients toward oral, subcutaneous, or longer-acting alternatives.
What formulations are protected by Ocrevus patents and regulatory exclusivity?
The intravenous formulation remains the historical commercial base. Ocrevus Zunovo adds a subcutaneous formulation containing ocrelizumab with hyaluronidase-ocsq. Its commercial value is based on administration convenience rather than a new active ingredient.
The subcutaneous formulation may create separate intellectual-property and regulatory barriers involving:
- Drug concentration and excipient composition.
- Hyaluronidase combination technology.
- Injection volume and administration time.
- Container-closure systems.
- Stability and storage.
- Device or administration components.
- Patient-selection and conversion instructions.
The subcutaneous product does not restart the full 12-year U.S. reference-product exclusivity period for ocrelizumab. It may receive separate limited exclusivity for qualifying new clinical investigations, but that protection does not replace the original reference-product exclusivity period.
What is the FDA regulatory status of Ocrevus?
Ocrevus has full FDA approval for:
- Relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
- Primary progressive multiple sclerosis.
Ocrevus Zunovo was approved in 2024 for the same broad disease populations, subject to label-specific administration requirements. Patients generally receive an initial intravenous dose before transitioning to the subcutaneous product.
The regulatory profile reduces clinical adoption risk because Roche does not need to establish a new therapeutic indication. The primary commercial task is converting patients and infusion centers to the new delivery format.
How does Ocrevus compare with competing multiple sclerosis drugs?
| Product or class |
Company |
Main competitive advantage |
Main Ocrevus threat |
| Kesimpta, ofatumumab |
Novartis |
At-home monthly subcutaneous dosing |
Convenience and direct-to-patient administration |
| Briumvi, ublituximab-xiy |
TG Therapeutics |
Anti-CD20 mechanism and shorter infusion profile |
Same-class competition |
| Tysabri, natalizumab |
Biogen |
High efficacy and established use |
Alternative high-efficacy treatment |
| Gilenya, fingolimod |
Novartis |
Oral dosing and long market history |
Oral convenience |
| Mavenclad, cladribine |
Merck KGaA |
Short-course treatment model |
Reduced treatment frequency |
| Interferons and glatiramer acetate |
Multiple companies |
Lower cost and established experience |
Price-driven substitution |
Ocrevus has an important advantage over many oral therapies in primary progressive multiple sclerosis, where treatment options are more limited. In relapsing disease, competition is more intense because patients and physicians can choose among oral, injectable, infusion, and subcutaneous therapies.
What generic entry risks exist for Ocrevus?
The likely entry path is biosimilar competition rather than generic competition. The most probable scenarios are:
Early biosimilar entry after 2029
A biosimilar could enter soon after U.S. reference-product exclusivity expires if the sponsor has completed development and resolved patent issues. This would create the greatest price and share risk.
Delayed entry caused by patents or litigation
Roche could assert remaining composition, formulation, dosing, or manufacturing patents. A settlement could establish a launch date later than the nominal 2029 exclusivity expiration.
Limited substitution
A biosimilar may initially obtain approval without automatic interchangeability. Physicians could prescribe it, but pharmacy-level substitution may remain limited. This would slow rapid conversion.
Franchise defense through Ocrevus Zunovo
Roche can use the subcutaneous formulation, contracting, patient services, and physician familiarity to retain patients. The strategy is likely to protect share rather than eliminate biosimilar pressure.
What patent litigation or settlement agreements affect ocrelizumab?
No major publicly reported U.S. Ocrevus biosimilar litigation or settlement was established through the available public record through 2024. That status can change as the 2029 exclusivity date approaches.
The most likely litigation issues are:
- Whether a biosimilar sponsor disclosed its application under the BPCIA.
- Whether Roche asserted antibody or formulation patents.
- Whether a biosimilar launch date was established by settlement.
- Whether a product is marketed as interchangeable.
- Whether method-of-use patents constrain labeling.
The absence of a disclosed settlement means the 2029 date remains the principal public regulatory benchmark, not a guaranteed commercial launch date.
How exposed is Roche to Ocrevus revenue loss?
Ocrevus is among Roche’s most important growth products. At approximately CHF 7.1 billion in 2024 sales, it represented a material share of Roche Pharmaceuticals revenue and a larger share of the company’s multiple sclerosis exposure.
Revenue risk will likely develop in phases:
| Period |
Expected commercial dynamic |
| 2025-2027 |
Continued growth, subcutaneous conversion, increasing payer scrutiny |
| 2028-2029 |
Pre-biosimilar contracting, inventory planning, and potential patent disputes |
| 2030-2032 |
Potential biosimilar price erosion and share loss |
| After 2032 |
Market segmentation between originator IV, originator subcutaneous, and biosimilar products |
A rapid 20% to 30% decline in net price or treated volume would create a multibillion-franc annual revenue exposure over time. The actual impact will depend on biosimilar interchangeability, payer mandates, contracting, physician behavior, and Roche’s ability to migrate patients to Ocrevus Zunovo.
Key Takeaways
- Ocrevus generated approximately CHF 7.1 billion in Roche sales in 2024, up from about CHF 6.4 billion in 2023.
- The drug has broad FDA approval for relapsing and primary progressive multiple sclerosis.
- U.S. reference-product biologic exclusivity expires on March 28, 2029.
- Ocrevus is not managed through a conventional Orange Book patent listing framework.
- No FDA-approved ocrelizumab biosimilar or major public U.S. biosimilar litigation was established through 2024.
- Ocrevus Zunovo provides a subcutaneous lifecycle-management strategy but does not reset the original 12-year biologic exclusivity period.
- The largest commercial threats are anti-CD20 competition, oral therapies, payer pricing pressure, and biosimilar entry after 2029.
- Roche’s patent and commercial defenses are strongest in formulation, delivery, manufacturing, and brand retention rather than in long-term exclusivity based solely on the antibody mechanism.
FAQs About Ocrelizumab Exclusivity and Market Competition
Is Ocrevus a biologic or a small-molecule drug?
Ocrevus is a biologic monoclonal antibody. Competing products would generally be developed as biosimilars under the FDA’s 351(k) pathway rather than as generic drugs.
Does Ocrevus have a biosimilar?
No FDA-approved ocrelizumab biosimilar was established through 2024. The first U.S. biosimilar approval opportunity is tied to the March 2029 expiration of reference-product exclusivity, subject to patent barriers.
Will Ocrevus Zunovo extend Ocrevus exclusivity to 2036?
No. The 2024 approval of Ocrevus Zunovo does not create a new 12-year reference-product exclusivity period for ocrelizumab. It may receive narrower protection associated with new clinical investigations and formulation patents.
Is Kesimpta a biosimilar to Ocrevus?
No. Kesimpta contains ofatumumab, a different anti-CD20 monoclonal antibody. It is a competing branded biologic, not an ocrelizumab biosimilar.
What is the greatest long-term risk to Ocrevus sales?
The greatest long-term risk is combined competition from anti-CD20 products, high-efficacy oral therapies, and biosimilars after 2029. Price erosion may occur before substantial patient switching if payers use formulary controls and contracting to favor lower-cost alternatives.
References
-
European Medicines Agency. (2018). Ocrevus: EPAR - product information. https://www.ema.europa.eu/
-
Roche. (2023). Annual report 2023. https://www.roche.com/
-
Roche. (2024). Annual report 2024. https://www.roche.com/
-
U.S. Food and Drug Administration. (2017). FDA approves new drug to treat multiple sclerosis. https://www.fda.gov/
-
U.S. Food and Drug Administration. (2020). Biosimilar and interchangeable biosimilar biological products. https://www.fda.gov/
-
U.S. Food and Drug Administration. (2024). FDA approves Ocrevus Zunovo for multiple sclerosis. https://www.fda.gov/
